PyInvesting

Market research

TARO Taro Pharmaceutical Industries Ltd

NYSE USD Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
2B
P/E ratio
30.05
Analyst target
43
Dividend yield
Not available
Beta
0.56

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

Taro Pharmaceutical Industries Ltd is currently in a long term uptrend where the price is trading 2.1% above its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.0.

Taro Pharmaceutical Industries Ltd's total revenue sank by 5.1% to $140M since the same quarter in the previous year.

Its net income has dropped by 51.4% to $33M since the same quarter in the previous year.

Finally, its free cash flow fell by 59.1% to $38M since the same quarter in the previous year.

Based on the above factors, Taro Pharmaceutical Industries Ltd gets an overall score of 2/5.